Kezar Life Sciences, Inc. (KZR)
NASDAQ: KZR · Real-Time Price · USD
6.20
-0.15 (-2.36%)
At close: Mar 27, 2026, 4:00 PM EDT
6.46
+0.26 (4.24%)
After-hours: Mar 27, 2026, 5:01 PM EDT
Kezar Life Sciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
45.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 7.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xilio Therapeutics | 43.77M |
| Metagenomi Therapeutics | 25.21M |
| Radiopharm Theranostics | 10.86M |
| GeoVax Labs | 3.35M |
| Nutriband | 2.28M |
| Rallybio | 858.00K |
| Lisata Therapeutics | 170.00K |
| Entera Bio | 124.00K |
KZR News
- 17 days ago - Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences - Business Wire
- 2 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis - Business Wire
- 4 months ago - Kezar Life Sciences Reports Third Quarter 2025 Financial Results - Business Wire
- 5 months ago - Kezar Life Sciences Announces Presentation of PORTOLA Data at the American Association for the Study of Liver Disease (AASLD) – The Liver Meeting® 2025 - Business Wire
- 5 months ago - Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis and Plans to Explore Strategic Alternatives - Business Wire
- 7 months ago - Kezar Life Sciences to Participate in Two Upcoming Investor Conferences - Business Wire
- 8 months ago - Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 9 months ago - Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis - Business Wire